Summary
This multi-centre, multi-laboratory study examined prognostic markers in 1058 invasive bladder cancer patients who underwent radical cystectomy, comparing the independent and combined predictive value of FGFR3 mutations against P53 and KI-67 immunohistochemical expression. The analysis as suggested by the title sought to establish which biomarker or combination thereof best stratifies patient risk and informs treatment decisions in this patient population. Results may contribute to standardisation of molecular and immunohistochemical testing protocols in bladder cancer pathology across European centres.
UK applicability
Findings are relevant to UK urological oncology practice, particularly for pathology laboratories and cancer centres standardising biomarker testing in invasive bladder cancer. The multi-laboratory design may inform harmonisation of testing protocols across NHS histopathology services.
Key measures
FGFR3 mutation status, P53 expression, KI-67 expression, disease-free survival, overall survival, recurrence-free survival
Outcomes reported
The study compared prognostic value of FGFR3 mutation status versus P53 and KI-67 expression in predicting outcomes in invasive bladder cancer patients. A multi-centre, multi-laboratory analysis was conducted across 1058 radical cystectomy patients to assess the independent and combined predictive power of these molecular and immunohistochemical markers.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.